Stoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They currently have a $22.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 80.33% from the stock’s previous close.

Other analysts also recently issued reports about the stock. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 26th. JPMorgan Chase & Co. increased their price target on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a report on Tuesday, March 26th. Finally, Canaccord Genuity Group increased their price target on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.71.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK traded up $0.18 during trading on Monday, reaching $12.20. The company had a trading volume of 159,354 shares, compared to its average volume of 955,190. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.40. The firm has a market capitalization of $635.86 million, a PE ratio of -5.10 and a beta of 0.82. The firm’s fifty day moving average is $10.05 and its 200 day moving average is $6.57.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.02. The firm had revenue of $2.80 million for the quarter, compared to analyst estimates of $3.70 million. Equities analysts predict that Stoke Therapeutics will post -2.28 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Edward M. Md Kaye sold 11,150 shares of the stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now owns 69,350 shares in the company, valued at approximately $423,035. The sale was disclosed in a filing with the SEC, which is available at this link. In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares in the company, valued at approximately $126,550.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the sale, the chief executive officer now owns 69,350 shares of the company’s stock, valued at approximately $423,035. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,622,741 shares of company stock worth $41,935,115. 11.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Dorsey & Whitney Trust CO LLC bought a new stake in shares of Stoke Therapeutics in the third quarter worth $43,000. Sherbrooke Park Advisers LLC acquired a new position in shares of Stoke Therapeutics in the third quarter valued at about $48,000. SG Americas Securities LLC acquired a new stake in Stoke Therapeutics during the third quarter worth about $53,000. Corton Capital Inc. bought a new position in shares of Stoke Therapeutics in the third quarter worth about $58,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Stoke Therapeutics in the third quarter worth about $64,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.